drugset
drugset / Trial / NCT00258427

Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia

NCT00258427 ↗

Phase 2 Completed 14 enrolled Masonic Cancer Center, University of Minnesota
Non-randomizedSingle-groupOpen-labelTreatment

Summary

RATIONALE: A bone marrow or umbilical cord blood transplant may be able to replace blood-forming cells that were destroyed by chemotherapy. Giving combination chemotherapy before a donor stem cell transplant may make the transplant more likely to work. This may be an effective treatment for patients with high risk Fanconi's anemia. PURPOSE: This clinical trial is studying how well combination chemotherapy works in treating high risk patients who are undergoing a donor stem cell transplant for Fanconi's anemia.

Timeline

Start
2002-03-26
Primary completion
2020-10-10
Completion
2020-10-10

Drugs

EvaluationDrugModalityDoseRoute
Background ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) Protein / enzyme biologic 15 mg/kg Intravenous
Background Busulfan Small molecule 0.8 mg/kg Intravenous
Background Busulfan Small molecule 1 mg/kg Intravenous
Background Cyclophosphamide Other / unclassified 10 mg/kg Intravenous
Background Fludarabine Small molecule 35 mg/m2 Intravenous
Background Methylprednisolone Other / unclassified 1 mg/kg Intravenous
Background filgrastim Protein / enzyme biologic 5 ug/kg Intravenous

Indications

Fanconi anemia